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Summary
 
The role of apoptosis in affinity maturation was investigated by determining the affinity of
(4-hydroxy-3-nitrophenyl)acetyl (NP)-specific antibody-forming cells (AFCs) and serum anti-
body in transgenic mice that overexpress a suppressor of apoptosis, Bcl-x
 
L
 
, in the B cell com-
partment. Although transgenic animals briefly expressed higher numbers of splenic AFCs after
immunization, the 
 
bcl-x
 
L
 
 
 
transgene did not increase the number or size of germinal centers
(GCs), alter the levels of serum antibody, or change the frequency of NP-specific, long-lived
AFCs. Nonetheless, the 
 
bcl-x
 
L
 
 
 
transgene product, in addition to endogenous Bcl-x
 
L
 
, reduced
apoptosis in GC B cells and resulted in the expansion of B lymphocytes bearing VDJ rearrange-
ments that are usually rare in primary anti-NP responses. Long-lived AFCs bearing these non-
canonical rearrangements were frequent in the bone marrow and secreted immunoglobulin G
 
1
 
antibodies with low affinity for NP. The abundance of noncanonical cells lowered the average
affinity of long-lived AFCs and serum antibody, demonstrating that Bcl-x
 
L
 
 and apoptosis influ-
ence clonal selection/maintenance for affinity maturation.
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A
 
distinct property of humoral immune responses to T
cell–dependent antigens is a progressive increase in
antibody affinity known as affinity maturation (1, 2). Affin-
ity maturation is achieved by two key events: the generation
of antibody variants by V(D)J hypermutation and the sub-
sequent selection of those variants that bind antigen strongly
(3, 4). It is widely believed that the selective accumulation
of high-affinity B cells is mediated by inter- and intraclonal
competition for antigen retained on follicular dendritic cells
(FDCs)
 
1
 
 in germinal centers (GCs) (5–7). However, little is
known about the cellular and molecular mechanisms un-
derlying this selection.
GCs serve as a crucial site for antigen-driven V(D)J hyper-
mutation (8, 9). Clonal selection and affinity maturation
within this mutated population can be followed by a variety
of methods (10, 11) to show that increased affinity is achieved
by both preferential retention of higher-affinity B cells (posi-
tive selection) and loss of low-affinity B cells (negative selec-
tion). Although positive selection can only result from an ac-
tive process, i.e., selective proliferation, negative selection can
arise passively. For example, limiting amounts of antigen may
be insufficient to activate B cells with low-affinity receptors
(12) or to support their interaction with T lymphocytes (13).
Such clones would be rapidly overgrown in the GC popula-
tion by higher-affinity competitors. Nonetheless, negatively
selected GC B cells are believed to die by apoptosis, because
GCs are sites of considerable cell death, and in vitro
 
,
 
 GC B
cells undergo programmed cell death in the absence of acti-
vating stimuli (14). Furthermore, administration of large
amounts of soluble antigen sharply elevates the number of
apoptotic B cells in GCs, an experiment thought to mimic
the negative selection of autoreactive mutants (15–17).
Several molecules that regulate apoptosis have been pro-
posed to modulate negative selection during affinity matu-
ration. Bcl-2, an inhibitor of apoptotic cell death, is selec-
tively downregulated in GC B cells (18), and human GC B
cells rapidly become apoptotic in ex vivo culture. How-
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; BCR, B cell
antigen receptor; BM, bone marrow; BrdU, 2-bromodeoxyuridine; CG,
chicken 
 
g
 
-globulin; ELISPOT, enzyme-linked immunospot; FDC, follicu-
lar dendritic cell; GC, germinal center; HRP, horseradish peroxidase; mIg,
membrane Ig; NP, (4-hydroxy-3-nitrophenyl)acetyl; PNA, peanut aggluti-
nin; R/S ratio, ratio of replacement to silent mutations; TUNEL, terminal
deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling. 
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ever, stimulation of human GC B cells with antibody to
membrane Ig (mIg) or CD40 extends the survival of cul-
tured GC cells and upregulates Bcl-2 (14). Reciprocally, a
positive regulator of apoptotic cell death, Fas (CD95), is
highly expressed in GC B cells (18, 19), and GC B cells are
susceptible to Fas-mediated apoptosis in vitro (20, 21). De-
spite these in vitro models, studies of genetically modified
mice do not support major roles for Bcl-2 or Fas in affinity
maturation. Neither the overexpression of Bcl-2 nor the
lack of Fas has detectable effects on the affinity maturation
of serum antibodies (19, 22). These findings raise the possi-
bility that affinity maturation is achieved solely by positive
selection, or that other apoptosis-regulatory molecules are
involved in the negative selection process.
A homologue of 
 
bcl-2
 
, 
 
bcl-x
 
, also suppresses apoptosis
through its Bcl-x
 
L
 
 product (23). Bcl-x
 
L
 
 is highly expressed
in pre-B cells but is downregulated when B cells enter the
mature pool (24, 25). While Bcl-2 plays a critical role in
the survival of mature naive lymphocytes (26), Bcl-x
 
L
 
 is
important for the survival of immature lymphocytes (27).
Interestingly, cross-linking of mIg or CD40 on splenic B
cells upregulates the expression of Bcl-x
 
L
 
 (25, 28). Human
GC B cells are also known to reexpress Bcl-x
 
L
 
, with ex-
pression confined to the centrocyte subset in which clonal
selection is thought to occur (29, 30). These data and the
many shared characteristics of immature and GC B cells
(31) suggest that Bcl-x
 
L
 
 might control life-or-death deci-
sions in the GC compartment.
To examine the roles of apoptosis and Bcl-x
 
L
 
 in affinity
maturation, we tracked the affinity of antibody-forming
cells (AFCs) in the bone marrow (BM) and serum antibody
of 
 
bcl-x
 
L
 
 
 
transgenic mice and their congenic wild-type con-
trols, during the clonally restricted antibody response to the
(4-hydroxy-3-nitrophenyl)acetyl (NP) hapten (32). Our
study revealed that overexpression of Bcl-x
 
L
 
 did not change
the magnitude of the GC response or the frequency of
AFCs in the BM. However, apoptotic cell death in GCs
was significantly reduced in 
 
bcl-x
 
L
 
 
 
transgenic mice and led
to the persistence of many B cells carrying VDJ rearrange-
ments that are normally rare in the later stages of the pri-
mary anti-NP response and generally encode lower-affinity
antibody (11, 12, 32). Affinity maturation of serum IgG
 
1
 
antibody was reduced in transgenic mice by the persistence
of low-affinity BM AFCs. Selective apoptosis, rather than
the overgrowth of high-affinity clones, appears to be the
prime agency by which low-affinity B cells are lost from
humoral responses.
 
Materials and Methods
 
Antigens and Antibodies.
 
The succinic anhydride ester of NP
was reacted with chicken 
 
g
 
-globulin (CG; Sigma Chemical Co.)
or BSA (U.S. Biochemical Corp.) as described (32). The coupling
ratio of each conjugate was determined spectrophotometrically.
Antibodies specific for IgM
 
b
 
 (AF6-78) and mouse 
 
l
 
1 L chain
(Ls136) were purified over protein G–Sepharose (Amersham
Pharmacia Biotech) from culture supernatants. Horseradish per-
oxidase (HRP)-conjugated goat anti–mouse IgG
 
1
 
 and biotin-
 
ylated anti-IgD antibodies were purchased from Southern Bio-
technology Associates. Anti-Fc
 
g
 
RI/RII (2.4G2), FITC-labeled
GL-7, PE-conjugated anti-B220, biotinylated anti–Mac-1, –Gr-1,
-Thy1.2, -CD4, -CD8, and -Ter119, and PE-conjugated anti-
CD138 (syndecan) antibodies were purchased from PharMingen.
Anti–Bcl-x and anti–Bcl-2 mAbs were purchased from Trans-
duction Laboratories.
 
Mice and Immunizations. bcl-x
 
L
 
 
 
transgenic mice were generated
as described previously (24) and backcrossed with the C57BL/6
strain (The Jackson Laboratory). 
 
Igh
 
b
 
 progeny were used in all ex-
periments. 
 
bcl-x
 
L
 
 
 
transgenic or transgene-negative littermate con-
trol mice were immunized intraperitoneally with 50 
 
m
 
g of an
NP
 
20
 
-CG conjugate precipitated in alum.
 
Enzyme-linked Immunospot Assay and Affinity Estimates.
 
The
frequencies of NP-specific AFCs in spleen and BM were estimated
by enzyme-linked immunospot (ELISPOT) assay using two dif-
ferent coupling ratios of NP-BSA (11). In brief, splenocytes (10
 
5
 
cells/well) or BM cells (5 
 
3 
 
10
 
5
 
 cells/well) were incubated on ni-
trocellulose filters coated with NP
 
2
 
-BSA, NP
 
23
 
-BSA, or BSA
alone at 37
 
8
 
C, 5% CO
 
2
 
 for 2 h. After washing, filters were stained
with HRP-conjugated anti-IgG
 
1
 
 antibodies, and HRP activities
were visualized using 3-aminoethyl carbazole. The frequencies of
high-affinity and total AFCs were determined from NP
 
2
 
-BSA–
and NP
 
23
 
-BSA–coated filters after background on BSA-coated
filters was subtracted.
 
ELISA Titration of Serum IgG
 
1 
 
Antibody and Affinity Estimates.
 
IgG
 
1 
 
specific for the NP hapten was detected by ELISA using two
different coupling ratios of NP-BSA as described (11). In brief,
serially diluted sera were added to plates coated with NP
 
2
 
-BSA or
NP
 
23
 
-BSA and incubated at 4
 
8
 
C overnight. After washing, HRP-
conjugated goat anti–mouse IgG
 
1
 
 was added, and HRP activity
was visualized using a TMB peroxidase substrate kit (Bio-Rad
Laboratories). The concentrations of anti-NP IgG
 
1 
 
antibodies
were estimated by comparison with standard curves created from
the H33L
 
g
 
1/
 
l
 
1 control antibody on each plate (12). To estimate
the affinity of NP-binding antibody in the sera, ratios of NP
 
2
 
-
binding antibody to NP
 
23
 
-binding antibody were calculated.
 
Histology.
 
All histological procedures were conducted as de-
scribed previously (32). The number of 
 
l
 
1
 
1
 
 GCs was determined
by staining sections with biotinylated Ls136, followed by alkaline
phosphatase–conjugated streptavidin (Southern Biotechnology
Associates) and HRP-conjugated peanut agglutinin (PNA). Apop-
totic cell death in GCs was estimated by terminal deoxynucleo-
tidyl transferase–mediated dUTP-biotin nick end labeling (TUNEL)
as described (17). TUNEL
 
1
 
 cells in GCs were counted at 200
 
3
 
magnification by systematic scanning. Cell proliferation in GCs was
determined by the incorporation of 2-bromodeoxyuridine (BrdU)
as described (33). In brief, 10 d after immunization, 
 
bcl-x
 
L
 
 
 
trans-
genic and control mice were given 1.0 mg BrdU by intraperito-
neal injection; 2 h later, the mice were killed and their spleens
prepared for histology. Proliferation indices were determined by
microscopic inspection as the fraction (%) of PNA-binding
(PNA
 
1
 
) cells that exhibited nuclear BrdU incorporation.
 
Sequence Analysis of VDJ Rearrangements from GC B Cells.
 
l
 
1
 
1
 
GC cells were microdissected from day 12 spleen sections of 
 
bcl-x
 
L
 
transgenic mice and control mice. VDJ DNA was amplified by
PCR and cloned into Bluescript plasmid (34). The frequency of
VDJ genes using the V186.2 gene segment was estimated by col-
ony hybridization using oligonucleotides specific for V186.2 and
one specific for the framework 3 region of the mouse V
 
H
 
 V186.2
and V3 subfamilies of the J558 group (32, 35). Plasmid DNA was
extracted from 
 
#
 
3 bacterial colonies from each GC, and V
 
H
 
 gene
sequences were determined by automated sequencing. 
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Flow Cytometry.
 
Single cell suspensions of splenocytes and BM
cells were prepared as described (11). Cells were then washed in
PBS (pH 7.4) containing 2% FCS and 0.08% sodium azide at 4
 
8
 
C
for cytometric analysis, or washed with deficient RPMI 1640 (Ir-
vine Scientific) containing 2% FCS for sorting. The enumeration
of GC B cells and sorting of BM AFCs were carried out as de-
scribed (11).
To collect GC B cells, splenocytes pooled from four mice were
blocked with anti-Fc
 
g
 
RI/RII and then stained with biotinylated
anti-IgD, –Mac-I, –Gr-1, -Thy1.2, -CD4, -CD8, and -Ter119
antibodies for 30 min. After three washes, cells were incubated
with streptavidin-conjugated microbeads (Miltenyi Biotec) for 15
min. Cells attached to microbeads were depleted by passage
through a CS column (Miltenyi Biotec) in a magnetic field based
on the manufacturer’s protocol. Recovered cells were stained
with FITC-labeled GL-7, PE-conjugated anti-B220, Tricolor-
conjugated streptavidin (Caltag Laboratories), and 7-amino-actino-
mycin D (7-AAD). Finally, GL-7
 
1
 
B220
 
1
 
 cells within the
Tricolor
 
2
 
7-AAD
 
2
 
 
 
fraction were sorted into biotin-deficient
RPMI containing 2% FCS using a FACStar
 
Plus™
 
 (Becton Dickin-
son). GL-7
 
2
 
B220
 
1
 
 
 
cells were sorted from the same pooled sple-
nocytes without preenrichment by depletion with magnetic beads.
To collect B220
 
1
 
 
 
cells and CD3
 
1
 
 
 
cells, splenocytes from naive
 
bcl-x
 
L
 
 
 
transgenic and control mice were blocked and stained with
FITC-labeled anti-CD3 and PE-conjugated anti-B220 antibody,
and then single positive cells were sorted by the same procedure.
Sorting routinely yielded populations of 
 
.
 
97% purity.
 
Western Blots.
 
Cells were lysed in a buffer containing 137 mM
NaCl, 1 mM MgCl
 
2
 
, 0.1 mM CaCl2, 20 mM Tris-HCl (pH 9.0),
1% NP-40, and 10% glycerol. After homogenization, cells were
centrifuged and supernatants were recovered. The cell lysates
were loaded (10 mg protein) onto 12% SDS polyacrylamide gel
and resolved by electrophoresis. The proteins were then transferred
by electrophoresis onto polyvinylidene fluoride membranes. After
blocking with TBS (Tris-buffered saline) containing 5% nonfat dry
milk, the membranes were incubated with 1:500 diluted anti–Bcl-x
or anti–Bcl-2 mAbs, then washed five times with TBS containing
0.1% Tween-20. After incubation with 1:20,000 diluted HRP-
conjugated goat anti–mouse Ig antibodies (Amersham Pharmacia
Biotech), the reaction was developed by enhanced chemilumi-
nescence using the ECL kit (Amersham Pharmacia Biotech) and
detected by exposure to X-ray film.
Results
bcl-xL Transgene Protects B Cells from Passive Apoptotic Death.
Spleens of mice carrying the bcl-xL transgene are z50%
larger and contain 30% more mononuclear cells than those
of nontransgenic littermates. This increased cellularity is
due to a near doubling in the number of mature IgM1
B2201 cells (Fig. 1 A). Flow cytometric analyses of splenic
B cells from transgenic mice revealed that expression of
IgM, IgD, CD19, CD21, CD22, CD23, and CD24 was
identical to that of control littermates (data not shown).
Despite the increased numbers of peripheral B lympho-
cytes, transgenic animals displayed normal levels of serum
IgM (1,242 ± 351 vs. 1,295 ± 379 mg/ml) and IgG (1,341 ±
101 vs. 1,777 ± 379 mg/ml) as measured by specific ELISA.
As expected (24), the thymic and peripheral T cell com-
partments of transgenic mice were normal in size and cellu-
lar composition (Fig. 1 A, and data not shown).
Initial assays were performed to assess the ability of trans-
gene-bearing B cells to survive in culture medium contain-
ing little FCS. Purified splenic B cells from transgenic mice
showed a significant survival advantage over control cells
Figure 1. B cells from bcl-xL transgenic mice are resistant to passive cell death and proliferate in vitro in response to activated helper T cell clones or re-
combinant CD40L. (A) The bcl-xL transgene expands the peripheral B cell compartment. Transgenic animals exhibit increased splenic cellularity that re-
flects a near doubling of naive IgM1 B lymphocytes. In contrast, thymic weight and cellularity are unchanged. Values represent mean ± SEM of six to
nine bcl-xL transgenic mice or wild-type littermate controls. Splenic weight, cellularity, and B cell number are significantly (P , 0.01) greater in trans-
genic mice than in normal controls. (B) Splenic B cells were purified from control (filled symbols) or transgenic (open symbols) mice and cultured in me-
dium containing 1% FCS for 96 h. Viable cells present in triplicate cultures were enumerated by trypan blue exclusion at the indicated times; each point
represents the mean number (± SD) of viable B lymphocytes. (C) Purified control and transgenic B cells (1.5 3 105 cells/well) were cultured for 48 h in
the presence of helper T cells activated by immobilized CD3-specific antibody (squares) or rCD40L (circles). [3H]Thymidine uptake by the cultured cells
was then determined to estimate cellular proliferation. Stimulating T cells were diluted threefold from 3 3 104 cells/well, and medium enriched for
rCD40L was serially diluted in threefold steps from 0.3%.402 Relaxed Affinity Maturation in  bcl-xL Transgenic Mice
when cultured in medium containing 1% (Fig. 1 B) or 0.1%
serum (not shown), indicating their strong resistance to the
effects of serum starvation.
Despite their resistance to serum starvation, transgenic B
cells displayed no evidence for increased proliferation in re-
sponse to CD40 cross-linking or T cell help in vitro (Fig.
1 C). In addition, proliferative responses and antibody pro-
duction in cultures containing LPS were the same for both
transgenic and control splenocytes.
Expression Pattern of Endogenous and Transgenic Bcl-xL in
Splenic Lymphocytes. The product of the bcl-xL transgene
carries a short epitope tag at its NH2 terminus and migrates
more slowly in SDS-PAGE gels than endogenous Bcl-xL,
which runs as a doublet at ø31 and 32 kD. Fig. 2 A illus-
trates that transgenic Bcl-xL is expressed almost exclusively
in the B2201 fraction of splenic lymphocytes. To define
transgene expression in B cells participating in an immune
response, C57BL/6 mice were immunized with NP-CG,
and 12 d later splenic B2201 cells were sorted into GL-72
and GL-71 fractions to identify follicular and GC B cells,
respectively (31). The expression of endogenous Bcl-2 and
of endogenous and transgenic Bcl-xL in these populations
were then compared (Fig. 2 B).
Follicular B (GL-72B2201) cells from wild-type mice
are positive for Bcl-2 but express little Bcl-xL. Both pro-
teins are abundant in the follicular population of mice car-
rying the bcl-xL transgene. In contrast, GC B cells (GL-71
B2201) isolated from both wild-type and transgenic mice
abundantly express Bcl-xL but little or no Bcl-2. This ob-
servation is consistent with studies of GCs in humans (18,
30). Thus, the reciprocal expression of Bcl-xL and Bcl-2 ob-
served in pre-B cells holds for GC B cells (24, 25). Interest-
ingly, although transgenic Bcl-xL is strongly expressed in
follicular B cells, only modest amounts of tagged Bcl-xL
could be demonstrated in GC B cells. Reverse transcription
PCR studies confirm lower steady state levels of transgenic
Bcl-xL message in the GL-71 B cell population (data not
shown). This biased expression of transgenic Bcl-xL may
represent distinct Em activity in each B cell compartment
(the density of mIg on GC B cells is #10% of that found
on follicular B cells [29]) or downregulation of the trans-
gene’s herpes TK promoter in activated cells (24).
GCs Develop Normally in bcl-xL Transgenic Mice. To assess
the effects of the bcl-xL transgene on GC development, we
compared the GC reaction of transgenic and control mice
at day 12 after immunization with NP-CG. This antigen
elicits a characteristic hapten-specific antibody that bears a l1
L chain and an H chain encoded by a canonical VDJ gene
rearrangement (32). We identified l11 GCs in spleen sec-
tions by labeling with PNA and anti-l1 antibody (32) and
determined the average number of l11 GCs per section
from groups of transgenic and control mice (Fig. 3 A). Dif-
ferences in the number or size (data not shown) of GCs
were not observed between the groups, nor did the mean
frequency of l11 GCs significantly differ between trans-
genic (35.4%) and wild-type mice (41.7%). When trans-
genic mice were immunized with carrier protein alone, the
average frequency of l11 GCs was 7.6%. Thus, frequent
l11 GCs in transgenic mice result from immunization with
NP rather than altered l1 L chain expression.
The frequencies of splenic GC B cells (GL-71B2201
fraction) in transgenic and control mice were also deter-
mined by flow cytometry. Both groups supported equiva-
lent and typical GC responses (Fig. 3 B): in transgenics, the
frequency of GC B cells peaked at an average of 2.46% of
splenocytes compared with 2.39% in controls at day 12 af-
ter immunization. Proliferative activity in the GC com-
partments of both transgenics and controls was also equiva-
lent; 10 d after immunization, 21 vs. 24% of PNA1 GC
cells were labeled by a 2-h pulse of BrdU (not shown).
Transgenic Bcl-xL Increases Splenic AFC Numbers but not
Their Longevity or Serum Antibody Titers. T cell–dependent
antigens induce two distinct populations of AFC, a short-
lived splenic population that generates the earliest primary
antibody and a long-lived set in the BM that maintains the
serum response (10, 11). Frequencies of NP-specific, IgG1
AFCs in the spleen and BM of transgenic and control mice
were determined by ELISPOT assay 12, 35, and 69 d after
immunization (Fig. 3 C). The kinetics of AFC production
were virtually identical in both groups of mice, but splenic
AFCs were threefold more abundant in transgenic mice
than in controls. This increase may reflect the approxi-
mately twofold increase in the number of B cells in the
spleens of transgenic mice (Fig. 1 A). Despite their greater
Figure 2. Expression of endogenous and transgenic Bcl-xL in spleno-
cytes. Expression patterns of Bcl-xL and Bcl-2 were determined by West-
ern blotting of splenocytes from bcl-xL transgenic mice or wild-type litter-
mate controls. (A) Unselected (total spenocytes [Total spl], lane 1),
lymphoid gate (lane 2), and sorted (B2201CD32, lane 3; B2202CD31,
lane 4) splenocytes were recovered from naive transgenic mice. Most, if
not all, transgenic Bcl-xL protein detected in these populations is confined
to splenic B lymphocytes. (B) Spleen cells from four immunized trans-
genic or wild-type mice were pooled at day 12 after immunization. 10 mg
of cell lysate protein was immunoblotted using anti–Bcl-x (upper panel)
or anti–Bcl-2 (lower panel) mAbs. Molecular masses: transgenic Bcl-xL,
33 kD; endogenous Bcl-xL, 31, 32 kD; Bcl-2, 26 kD. Transgenic Bcl-xL
protein is abundant in follicular (GL-72B2201) B cells, but only modest
amounts are present in GC B lymphocytes (GL-71B2201). Endogenous
Bcl-xL is expressed at low levels in follicular B cells but is upregulated in
the GC. In contrast, Bcl-2 is present in quantity in the follicular popula-
tion but undetectable in GC B cells.403 Takahashi et al.
numbers, splenic AFCs in transgenic mice were lost at the
same rate as in control animals. This rapid decline contrasts
with bcl-2 transgenic mice, which support higher numbers
and longer-lived splenic AFCs (22). Frequencies and kinetics
of specific BM AFCs were indistinguishable between trans-
genic and control mice (Fig. 3 C).
The expanded splenic AFC pool in transgenic mice re-
sulted in a minor increase in serum antibody titers on day
12, but later levels of antibody did not differ significantly
between transgenic and control mice. In both groups, anti-
body concentrations were at maximal levels on day 12 and
then slowly declined to about one third of this peak by day
69 (Fig. 3 D). Thus, overexpression of Bcl-xL modestly ex-
pands recruitment into the splenic AFC pool but does not
change cellular recruitment into GCs, entry into the BM
AFC pool, or maintenance of long-lasting serum antibody.
bcl-xL Transgenic Mice Have Fewer Apoptotic Cells in GCs.
GCs contain more apoptotic lymphocytes as determined by
TUNEL than other regions of spleen (17). These TUNEL1
cells are thought to represent lymphocytes that have been
negatively selected during the GC response. We performed
TUNEL assays on spleen sections from transgenic and con-
trol mice to determine if the small addition of transgenic
Bcl-xL expressed in GC B cells was sufficient to reduce
programmed cell death. TUNEL1 cells in GCs from both
groups were counted by microscopic examination, and the
frequency of TUNEL1 cells per unit area was calculated.
These frequencies were subdivided into 12 categories, and
the distribution histogram for each category was plotted
(Fig. 4). GCs from bcl-xL transgenic mice contained fewer
TUNEL1 cells per unit area (P , 0.01) than those from
control mice (Fig. 4). The most common apoptotic index in
wild-type animals was 2.0–2.5 TUNEL1 cells/unit area
but only 1.0–1.5 in the bcl-xL transgenics. Perhaps more
significantly, .20% of GCs in control mice contained .3
TUNEL1 cells/unit area, whereas only 5% of GCs in bcl-xL
transgenic animals held 3.0–4.0 apoptotic cells/unit area
with no GCs in the 4.5–6.0 categories. Thus, a modest ad-
dition of Bcl-xL in transgene-bearing GC B cells leads to a
readily detectable decrease of TUNEL1 cells.
GC B Cells Using Noncanonical VDJ Rearrangements Are
More Frequent in bcl-xL Transgenic Mice. Initially, immuni-
Figure 3. bcl-xL transgenic
mice produce GC and IgG1 anti-
body responses that are similar to
control animals. Splenocytes
were recovered from transgenic
mice or wild-type controls at
various times after immuniza-
tion with NP-CG. (A) The
numbers of l11 GCs were de-
termined by histological staining
with anti-l1 antibody and PNA.
Each point represents the aver-
age number of l11 GCs per his-
tologic section ($3 sections rep-
resenting ø2/3 splenic area) in
single transgenic (open circles) or
wild-type (filled circles) mice.
(B) The percentage of GC B cells
in live lymphocytes was assessed
by flow cytometry using anti-B220
and anti–GL-7 antibodies. Each
point represents the frequency
mean (6 SD) of GC B cells (per-
centage of total lymphoid gate)
in single transgenic (open circles)
and control (filled circles) mice
8, 12, and 35 d after immuniza-
tion. (C) Numbers of NP-speci-
fic AFCs from BM (circles) and
spleen (squares) of bcl-xL trans-
genic (open) or littermate control
mice (filled) were determined by
ELISPOT using NP23-BSA as the
capture antigen. Frequencies of
AFCs in naive mice (day 0) from
both groups were ,0.2 3 1025.
(D) NP-specific serum antibody
from transgenic (open) or wild-
type control mice (filled) was de-
termined by ELISA using NP23-
BSA. The average values (6 SD)
for serum antibody concentrations
from five to seven individual mice
per time point are presented.404 Relaxed Affinity Maturation in  bcl-xL Transgenic Mice
zation with NP conjugates stimulates a broad population of
splenic B cells that bear the l1 L chain and H chain genes
made from the V186.2 and V3 subgroups of the J558 VH
gene family (34). Until day 6–7 of the primary response,
many GC B cells express VH gene segments that closely re-
semble the canonical V186.2 element but encode lower-
affinity NP-binding antibodies (12, 34, 36, 37; and Shimoda,
M., and G. Kelsoe, unpublished data). By day 10, the major-
ity of B cells bearing these noncanonical VH gene rearrange-
ments are replaced by higher-affinity cells bearing V186.2/
DFL16.1 rearrangements and a tyrosine-rich junctional mo-
tif, YYGS (12, 34). Thus, after day 10 the efficiency of affin-
ity-based competition is estimated by the ratio of GC B cells
bearing V186.2 versus noncanonical VH rearrangements.
Cells were microdissected from a total of 27 l11 GCs from
4 transgenic and 4 control mice 12 d after immunization
with NP-CG. VDJ rearrangements from both groups of
mice were amplified by PCR and cloned into bacteria, and
.600 bacterial colonies were then subjected to hybridization
using V186.2-specific and subgroup-specific primers. About
80% (64/81) of VDJ rearrangements recovered from control
mice selectively hybridized to the V186.2 VH gene segment,
consistent with previous studies (12, 34), whereas fewer than
half (261/554) of the VDJ fragments amplified from bcl-xL
transgenic mice exhibited preference for V186.2.
These hybridization data were confirmed by sequencing
VDJ inserts from representative bacterial colonies (Table I).
From normal C57BL/6 control mice, 79% (11/14) of se-
quenced VDJ rearrangements contained the V186.2 gene
segment, confirming our hybridization analysis and prior
sequence studies (33). In contrast, only 47% (17/36) of se-
quenced VDJ fragments from bcl-xL transgenics carried the
canonical V186.2 element (Table I). Noncanonical rear-
rangements from both control and transgenic mice con-
tained other VH genes from the V186.2 and V3 subfamilies
(35) commonly recovered in early primary anti-NP responses
(12, 34).
The use of noncanonical VDJ rearrangements by immu-
nized transgenic mice was not due to altered usage of VH
gene segments in naive l11 B cells. We recovered splenic
l11B2201 cells from unimmunized, transgenic, and wild-
type mice by fluorescence-activated cell sorting, amplified
their VDJ rearrangements with the PCR primers used to
study GC populations, and determined the ratios of VDJ
rearrangements containing V186.2 versus related VH genes.
There was no significant difference in the percentage of
V186.2 genes used by naive Bcl-xL transgenic mice (14%;
12/88) and naive controls (16%; 12/74). These observa-
tions suggest that even slight overexpression of Bcl-xL in
GC B cells leads to lower numbers of TUNEL1 GC cells
and the persistence of clones bearing noncanonical VDJ re-
arrangements that commonly encode low-affinity antibod-
ies present early in the primary response to NP.
The abundance of noncanonical VDJ rearrangements
was not associated with impaired positive selection. Pat-
terns of mutation in VDJ rearrangements containing the
Figure 4. bcl-xL transgenic mice show reduced numbers of TUNEL1
cells in GCs. Spleen sections were prepared from transgenic mice (white
bars) and wild-type control mice (black bars) at day 12 after immuniza-
tion. TUNEL assays were performed with staining by PNA to identify
GCs. The number of TUNEL1 cells present and the area of each GC
were determined under 2003 magnification from .500 GCs. Frequen-
cies of TUNEL1 GC cells/area were then calculated, and each frequency
was placed into 1 of 12 categories. The distributions of categories for
transgenic and wild-type controls are plotted.
Table I. Somatic Genetics of l11 GC Cells in bcl-xL Transgenic 
and Wild-type Mice 12 d after Immunization
bcl-xL Wild-type
V186.2 (% of total) 17 (47%) 11 (79%)
Other (% of total) 19 (53%) 3 (21%)
Average no. of mutations
in V186.2 3.5 4.3
R/S ratio
CDR1 (14.0/1)* 8.0/1 .1.0/1
CDR2 (4.3/1) .15.0/1 4.8/1
FW (3.1/1) 1.3/1 2.4/1
DFL16.1 (%)‡ 59 64
YYGS (%)§ 24 18
All mice were immunized with NP-CG. Complete sequence data
are available from EMBL/GenBank/DDBJ under accession nos.
AF065315-31 (bcl-xL) and AF065332-42 (wild-type).
*R/S ratio of VH V186.2 given random mutagenesis.
‡Percentage of rearrangements using DLF16.1 gene segments in all re-
arrangements of VH V186.2.
§Percentage of rearrangements encoding YYGS in CDR3 in all rear-
rangements of VH V186.2.405 Takahashi et al.
canonical V186.2 gene segment were similar in transgenic
and control mice, with no significant difference (P . 0.05)
in the ratios of replacement versus silent mutations (R/S
ratios) in CDRs (Table I). Other characteristics indicative
of high-affinity, NP-specific B cells, e.g., the fraction of re-
arrangements containing DFL16.1 and the YYGS CDR3
motif, were also similar in both groups. Thus, cellular re-
cruitment, V(D)J hypermutation, and positive selection in
GCs are unaffected by the bcl-xL transgene.
Transgenic Bcl-xL Leads to Impaired Affinity Maturation in
the BM AFC Compartment and Serum Antibody. Serum an-
tibody is maintained by long-lived BM AFCs that depend
on the GC differentiation pathway (10, 11, 38, 39). Affin-
ity maturation of serum antibody and the BM AFC com-
partment can be monitored by differential binding to ELISA
or ELISPOT substrates with sparse (NP2) or dense (NP23)
hapten coatings (10, 11). High-affinity antibody from se-
rum and AFCs binds equally well to both hapten densities,
whereas low-affinity binding is evident only on the NP23
substrate.
The high-affinity compartment of BM AFCs in wild-
type mice rapidly increased between days 12 (30.3%) and
35 (75.6%) of the response, with a more gradual increase
up to day 69 (88.4%) (Fig. 5 A). This kinetic is typical of
normal responses (11). At day 12, high-affinity AFCs were
as common in the BM of transgenic mice (34.3%) as in
controls. However, this population expanded more slowly
in animals with the bcl-xL transgene, reaching only 57.5 and
60.6% by days 35 and 69, respectively (Fig. 5 A). Remark-
ably, at day 69 of the response three transgenic mice had
smaller high-affinity AFC compartments than were present
at day 35, indicating little or no proliferation/survival ad-
vantage for high-affinity cells even when antigen concen-
trations should be minimal.
The average affinity of NP-specific serum antibody was
determined for the same mice by ELISA (Fig. 5 B). In
wild-type controls, early (day 12) serum antibody contained
little or no high-affinity component; by day 35 roughly half
of the serum antibody displayed high-affinity binding, and
by day 69 this value increased to .90% (Fig. 5 B). The av-
erage affinity of serum antibody in transgenic mice also in-
creased from day 12 to day 69, but again the extent of
affinity maturation was only z60% of controls. Overex-
pression of Bcl-xL led to diminished affinity maturation in
both BM AFCs and the serum antibody.
Impaired Affinity Maturation in Transgenic Mice Is Reflected
in the Somatic Genetics of the BM AFCs. To determine the
cause of decreased affinity in the BM AFCs of transgenic
mice, we recovered the l11 BM AFC populations from
immunized wild-type (n 5 5) and transgenic (n 5 5) mice
by cell sorting (11). Typically, at day 69 after immunization
.50% of sorted cells from both groups of mice secreted
IgG1 antibody specific for NP. Enriched BM AFC popula-
tions were subjected to a reverse transcription PCR that
preferentially amplifies cDNA representing rearrangements
of the V186.2 and V3 subfamilies of VH gene segments
joined to Cg1 (11). Amplified VDJ rearrangements were
cloned and sequenced to identify the VH and D gene seg-
ments used and any mutations present. Table II summarizes
this work and shows that only half (11/21) of the VDJ se-
quences recovered from bcl-xL transgenic mice used the
V186.2 gene segment. In contrast, nearly all (16/17) VDJ
rearrangements from wild-type mice contained the V186.2
gene segment. Thus, the high frequency of B cells bearing
noncanonical VDJ rearrangements present in day 12 GCs
(47%; Table I) was maintained in the day 69 BM AFC
population (53%) of mice with the bcl-xL transgene. The
reduced average affinity of BM AFCs in bcl-xL transgenic
mice results from the retention of B cells bearing nonca-
nonical VDJ rearrangements. Interclonal competition in both
Figure 5. bcl-xL transgenic mice show re-
laxed affinity maturation of NP-specific
IgG1 BM AFCs and serum antibody. The
average affinities of BM AFCs (A) and se-
rum antibodies (B) produced by transgenic
(open circles) and control (filled circles)
mice at different time points were esti-
mated. (A) The frequencies of NP2- and
NP23-specific IgG1 AFCs from BM were
determined by ELISPOT. Ratios of NP2
versus NP23-specific AFCs were then calcu-
lated and plotted. AFC affinities are signifi-
cantly (P , 0.05) lower in transgenic ani-
mals at 35 and 69 d after immunization. (B)
Concentrations of NP2- and NP23-specific
IgG1 antibody were determined by ELISA,
and the ratios of NP2- versus NP23-specific
IgG1 antibody were plotted. Each point
represents the ratio determined in a single
mouse. The average affinity of serum anti-
body in transgenic mice is significantly (P ,
0.05) lower than that of controls at 69 d af-
ter immunization.406 Relaxed Affinity Maturation in  bcl-xL Transgenic Mice
the GC and BM AFC compartments of transgenic mice is
relaxed, even when the amounts of residual antigen are
thought to be limiting.
Comparison of the frequency and pattern of mutations
in rearranged V186.2 gene segments from transgenic and
control mice suggests that intraclonal selection may also be
weakened by increased Bcl-xL expression. The average fre-
quency of mutations in V186.2 VH gene segments from the
BM AFCs of bcl-xL transgenic mice was about twice as high
as that from control mice (Table II). B cells in transgenic
mice might better survive the GC environment than B cells
in control animals, allowing them to accumulate more mu-
tations before entering the long-lived AFC compartment
(11). Furthermore, R/S ratios in both CDR1 and CDR2
of these genes were lower in transgenic mice than in con-
trols. Higher R/S ratios in CDRs arise in part as a conse-
quence of antigenic selection. Other characteristics indica-
tive of high-affinity, NP-specific B cells, such as the
percentage of genes bearing DFL16.1, the YYGS CDR3
motif, and a Trp®Leu (W®L) mutation at position 33,
were also less common in transgenic mice than in controls.
Together, these data show that the bcl-xL transgene enhances
the survival of low-affinity GC B cells bearing noncanoni-
cal VDJ rearrangements, increases their accumulation of VDJ
mutations, and allows low-affinity GC cells to remain in
the BM AFC compartment. Persistence of this low-affinity
component does not come at the expense of positive selec-
tion for higher-affinity clones but by diminished apoptosis
in low-affinity B cells.
After day 35, the population of high-affinity BM AFCs
grew twice as fast in wild-type mice as in transgenics (Fig.
5) even though both groups supported equivalent numbers
of NP-specific, IgG1 AFCs (Fig. 3). Administration of anti-
CD154 antibody to abrogate the GC reaction and reduce
the genetic diversity present in the BM AFC compartment
(11, 40) enhanced this difference. Control mice that received
the CD154-specific antibody, MR1, on days 6, 8, and 10
after immunization had a high-affinity BM AFC compart-
ment of 15.1% at day 22 of the response that grew to
55.8% by day 69 (data not shown). Immunized transgenic
mice that received MR1 antibody began with a compara-
ble high-affinity AFC compartment, 12.0% at day 22, but
this population grew to only 22.0% by day 69. Thus, over-
expression of Bcl-xL also retards affinity maturation outside
the GC microenvironment.
Discussion
In this report, we have demonstrated that a bcl-xL trans-
gene reduces apoptosis in the GC reaction and impairs af-
finity maturation by sparing cells normally lost from the
primary response. This transgene also enhances the survival
of peripheral B cells in response to serum starvation in vitro
and rescues developing B lymphocytes with aberrant VDJ
rearrangements. These effects represent supplementation of
endogenous Bcl-xL activity; although Bcl-xL is abundant in
the GL-71B2201 GC cells of wild-type mice, Bcl-2 is not
(Fig. 2 B). Similar observations have been reported for hu-
man GC cells where Bcl-xL rather than Bcl-2 mediates the
CD40-dependent survival of centrocytes ex vivo (30).
This result contrasts with that of Bcl-2 overexpression,
which does not interfere with affinity maturation (22) but
permits the survival of mature autoreactive B cells in the
periphery (41). The bcl-x and bcl-2 transgenes also act dif-
ferently during negative selection in immature B cells, as
transgenic Bcl-xL has the ability to block negative selection
and promote developmental maturation, whereas autoreac-
tive cells transgenic for bcl-2 remain arrested in develop-
ment (42, 43). Given the similar reciprocal expression of
bcl-2 and bcl-x in GC B cells and pre-B cells, bcl-x may have
a distinct role in regulating the survival of B cells undergo-
ing selection via mIg or the pre-B cell antigen receptor
(BCR) (24, 30). Bcl-xL becomes abundant in B cells after
cross-linking mIg or CD40 (25, 28), and the fate of GC B
cells is controlled by these same signals (40). We speculate
that the degree or quality of mIg signaling in low-affinity B
cells does not induce Bcl-xL expression as effectively as in
high-affinity cells, and that this deficit leads to apoptosis.
That even a slight addition of transgenic Bcl-xL to the
higher levels of the endogenous protein in GC B cells leads
to significant effects on cell death and affinity maturation
indicates that GC B cells are quite sensitive to small changes
in levels of this death antagonist. The fate of lower-affinity
GC B cells appears to be determined by a regulatory
threshold of Bcl-xL.
Relaxed negative selection and the retention of low-
affinity B cells in transgenic mice did not alter the duration
Table II. Somatic Genetics of BM AFCs in bcl-xL Transgenic and 
Wild-type Mice 69 d after Immunization
bcl-xL Wild-type
V186.2 (% of total) 11 (52%) 16 (94%)
Other (% of total) 10 (48%) 1 (6%)
Average no. of mutations
in V186.2 10.3 4.3
R/S ratio
CDR1 (14.0/1)* 1.8/1 14.0/1
CDR2 (4.3/1) 3.1/1 8.2/1
FW (3.1/1) 2.1/1 1.5/1
DFL16.1 (% of total)‡ 46 69
YYGS (% of total)§ 27 44
W®L33 (% of total)i 18 25
All mice were immunized with NP-CG. Complete sequence data are
available from EMBL/GenBank/DDBJ under accession nos. AF065343-
63 (bcl-xL) and AF065364-80 (wild-type).
*R/S ratio of VH V186.2 given random mutagenesis.
‡Percentage of rearrangements using DLF16.1 gene segments in all re-
arrangements of VH V186.2.
§Percentage of rearrangements encoding YYGS in CDR3 in all rear-
rangements of VH V186.2.
iPercentage of all VH V186.2 rearrangements bearing a W®L mutation
in codon 33.407 Takahashi et al.
or magnitude of the GC response in bcl-xL transgenic mice
(Fig. 3). At 35 d after immunization, the splenic GC reac-
tion had ended both in transgenic (0.33% GL-71B2201
spleen cells) and control (0.37%) animals. This is the earliest
time after immunization that the numbers of splenic GL-
71 B2201 cells return to preimmune levels in normal mice
(11). Thus, the GC response appears to be regulated by fac-
tors beyond affinity-driven competition and selective apop-
tosis. The rise and fall of GCs depend on the presence of
antigen, sustained cell–cell interactions, and cues for cellu-
lar location (40, 44–47). It is not surprising that this impor-
tant immunological response is controlled by finer means
than that afforded by Darwinian competition alone.
Nie et al. (37) have reported that immunization of
C57BL/6 mice with complexes of antibody and antigen
elicits lower-affinity serum antibody and a genetically di-
verse GC reaction similar to that we observe in bcl-xL trans-
genic mice. These authors hypothesize that immune com-
plexes decorated with C3d efficiently recruit the CD21/
CD19/CD81 coreceptor to antigen-binding BCRs to re-
duce the threshold of B cell activation. Lowered activation
thresholds would result in reduced levels of affinity-driven
selection. Although Nie and colleagues describe a pheno-
type similar to that of bcl-xL transgenic mice, we think it is
unlikely that Bcl-xL reduces selection intensity by enhanc-
ing BCR signals. Background levels of IgM and IgG are
similar in the serum of transgenic and control mice, and
both contain only trace amounts of NP-binding IgG before
immunization. Thus, immune complexes are no more
likely to form in bcl-xL transgenics than in wild-type con-
trols after primary immunization. Our data do support the
notion that enhanced BCR signals, perhaps mediated by
coreceptor recruitment, result in reduced apoptosis; immu-
nization with immune complexes may facilitate Bcl-xL ex-
pression in responding B lymphocytes.
A possible mechanism for continued selection by apop-
tosis outside of GCs is competition among memory B cells
for restimulation (48, 49). However, memory B cells are
thought to regain Bcl-2 expression, and it would be sur-
prising if their survival depended also on Bcl-xL (18). Alter-
natively, selective competition among BM AFCs for anti-
gen might drive sustained affinity maturation. BM AFCs
express low levels of mIg (11) and could interact with anti-
gen depots in a Bcl-xL–dependent fashion. Indeed, plasma-
cytomas express Bcl-xL (50), and human plasma cells ex-
hibit high levels of Bcl-xL but low levels of Bcl-2 (51),
although it is unclear if these cells represent long- or short-
lived AFCs. It will be important to learn how BM AFCs
integrate the usually antagonistic processes of differentia-
tion to antibody secretion and cellular longevity so as to
maintain protective levels of serum antibody over long
time periods.
Our data provide strong evidence of a continuing role
for antigen in the maintenance of the long-lived AFC pool.
However, Manz et al. (38) have reported that the transfer
of BM AFCs into unimmunized recipients reconstitutes
long-term serum antibody and conclude that antigen is un-
necessary for the survival of these cells. Such experiments
are complicated by the possibility of coincidental transfer of
residual antigen (6, 7, 48), but we cannot exclude the pos-
sibility that post-GC selection acts on precursors of the
long-lived AFC pool. In this case, the characteristic somatic
genetic changes observed in BM AFCs (11; Tables I and II)
would first occur in the precursor population. Such selec-
tion would be antigen dependent and affinity driven. Re-
cent work on the longevity and affinity of BM AFCs and
serum antibody (our unpublished studies) support the im-
portance of antigen retention and/or BCR signaling in
shaping the long-lived AFC population. What remains un-
challenged is that affinity maturation of serum antibody
continues for months after primary immunization (1, 2, 11;
Fig. 5). Although this progressive increase in affinity could
be programmed in the early phase of the response, we sug-
gest that in some way antigen continues to exert selection
on the responding B cells.
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